Top

Published in:

01-07-2008 | Editorial

Lifting symptom burden—how far off the ground are we?

Authors: Mellar P. Davis, Jordanka Kirkova

Published in: Supportive Care in Cancer | Issue 7/2008

Excerpt

Patients with locally advanced or metastatic cancer present with multiple symptoms. A systematic review of symptoms in incurable cancer identified that 37 symptoms occurred in more than 10%, and five of them (fatigue, pain, lack of energy, weakness, and appetite loss) occurred in more than 50% [1]. Sixty nine percent of medical oncologists reported that patients with advanced incurable cancer constituted a significant part of their practice and for 22%, palliative chemotherapy was given to the majority of their practice [2]. …

Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94–104. JulPubMedCrossRef

Cherny NI, Catane R, European Society of Medical Oncology Taskforce on Palliative and Supportive Care (2003) Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survey by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer 98(11):2502–2510. Dec 1PubMedCrossRef

Cleeland CS, Reyes-Gibby CC (2002) When is it justified to treat symptoms? Measuring symptom burden. Oncology (Williston Park) 16(9 Suppl 10):64–70. Sep

Boyar M, Raftopoulos H (2005) Supportive care in lung cancer. Hematol Oncol Clin North Am 19(2):369–387. vii, AprPubMedCrossRef

Bukowski R, Cella D, Gondek K, Escudier B, Sorafenib TARGETs Clinical Trial Group (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30(3):220–227. JunPubMedCrossRef

Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T et al (2004) The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 13(1):137–154. FebPubMedCrossRef

Miaskowski C, Lee KA (1999) Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 17(5):320–332. MayPubMedCrossRef

Cleeland CS (2007) Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 37:16–21. 2(37):16–21PubMedCrossRef

Kirkova J, Walsh D (2007) (Sep) Cancer symptom clusters—a dynamic construct. Support Care Cancer 15(9):1011–1013PubMedCrossRef

10.

Gapstur RL (2007) Symptom burden: a concept analysis and implications for oncology nurses. Oncol Nurs Forum 34(3):673–680. MayPubMedCrossRef

11.

Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ et al (2004) A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11(5):279–292PubMedCrossRef

12.

Servaes P, Verhagen C, Bleijenberg G (2002) Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 38(1):27–43. JanPubMedCrossRef

13.

Visser MR, Smets EM, Sprangers MA, de Haes HJ (2000) How response shift may affect the measurement of change in fatigue. J Pain Symptom Manage 20(1):12–18. JulPubMedCrossRef

14.

Gondek K, Sagnier PP, Gilchrist K, Woolley JM (2007) Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. J Clin Oncol 25(32):5087–5093. Nov 10PubMedCrossRef

15.

Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR (2007) Pharmacologic treatment of cancer-related fatigue. Oncologist 12(Suppl 1):43–51PubMedCrossRef

16.

Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park) 16(9 Suppl 10):117–124. Sep

17.

Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS (2007) Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 μg every 2 weeks. Cancer 110(7):1629–1640. Oct 1PubMedCrossRef

18.

US Department of Health and Human Services. Patient-reported outcomes measures—use in medical product development to support labeling claims. 2006; Available at: http://www.fda.gov/cder/guidance/5460dft.pdf.

19.

Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021–1030. MayPubMedCrossRef

20.

Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY (2004) Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 58(5):1394–1404. Apr 1PubMedCrossRef

21.

Monk BJ, Huang HQ, Cella D, Long HJ 3rd, Gynecologic Oncology Group Study (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21):4617–4625. Jul 20PubMedCrossRef

22.

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413. JunPubMed

23.

Parliament MB, Danjoux CE, Clayton T (1985) Is cancer treatment toxicity accurately reported. Int J Radiat Oncol Biol Phys 11(3):603–608. MarPubMed

24.

Varricchio CG, Sloan JA (2002) The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst 94(16):1184–1185. Aug 21PubMed

25.

Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA (2007) A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109(4):787–795. Feb 15PubMedCrossRef

26.

Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R et al (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23(10):2145–2154. Apr 1PubMedCrossRef

27.

Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D et al (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374–5380. Dec 1PubMedCrossRef

28.

Barnes EA, Bruera E (2002) Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 12(5):424–428. Sep–OctPubMedCrossRef

29.

Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G et al (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin.Oncol 25(32):5070–5077. Nov 10PubMedCrossRef

30.

Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118(8):622–629. Apr 15PubMed

31.

Lai JS, Cella D, Chang CH, Bode RK, Heinemann AW (2003) Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 12(5):485–501. AugPubMedCrossRef

32.

Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28(2):172–191. JunPubMedCrossRef

33.

Dahele M, Skipworth RJ, Wall L, Voss A, Preston T, Fearon KC (2007) Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 33(6):676–685. JunPubMedCrossRef

34.

Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23(12):2606–2617. Apr 20PubMedCrossRef

35.

Osoba D (1999) What has been learned from measuring health-related quality of life in clinical oncology? Eur J Cancer 35(11):1565–1570. OctPubMedCrossRef

36.

Dooms CA, Pat KE, Vansteenkiste JF (2006) The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Rev Anticancer Ther 6(4):531–544. AprPubMedCrossRef

37.

Marsh S (2007) Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 11(2):79–82PubMed

38.

Chada S, Menander KB, Bocangel D, Roth JA, Ramesh R (2008) Cancer targeting using tumor suppressor genes. Front Biosci 13:1959–1967. Jan 1PubMedCrossRef

39.

Fallowfield LJ, Harper P (2005) Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 48(3):365–377. JunPubMedCrossRef

40.

Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161):771–775. Sep 19PubMed

41.

Hassan I, Cima RC, Sloan JA (2006) Assessment of quality of life outcomes in the treatment of advanced colorectal malignancies. Gastroenterol.Clin.North Am 35(1):53–64. MarPubMedCrossRef

42.

Kaiser R (2005) Antiemetic guidelines: are they being used? Lancet Oncol 6(8):622–625. AugPubMedCrossRef

43.

Nelson KA, Walsh D (2003) The business of palliative medicine—Part 3: The development of a palliative medicine program in an academic medical center. Am J Hosp Palliat Care 20(5):345–352. Sep–OctPubMedCrossRef

44.

Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL, Bruera E (2004) Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 27(6):481–491. JunPubMedCrossRef

45.

Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M, Khawam E et al (2002) The impact of a palliative medicine consultation service in medical oncology. Support. Care Cancer 10(4):337–342. MayPubMedCrossRef

46.

Walsh D, Zhukovsky DS (2004) Communication in palliative medicine: a pilot study of a problem list to capture complex medical information. Am J Hosp Palliat Care 21(5):365–371. Sep–Oct.PubMedCrossRef

47.

Jansman FG, Postma MJ, Brouwers JR (2007) Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25(7):537–562PubMedCrossRef

48.

Garcia SF, Cella D, Clauser SB, Flynn KE, Lai JS, Reeve BB et al (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25(32):5106–5112. Nov 10PubMedCrossRef

Title: Lifting symptom burden—how far off the ground are we?
Authors: Mellar P. Davis
Jordanka Kirkova
Publication date: 01-07-2008
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 7/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0401-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2008

“What concerns me is…” Expression of emotion by advanced cancer patients during outpatient visits

Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.

Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway

When morphine does not work

Dying cancer patients’ experiences of powerlessness and helplessness

Self-reported experience and outcomes of care among stomach cancer patients at a median follow-up time of 27 months from diagnosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer